NCT03929029 2026-01-05
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT01810016 2022-10-12
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT00112242 2020-06-18
Immunotherapy of Stage III/IV Melanoma Patients
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT01308294 2020-06-11
LAG-3/IMP321
Centre Hospitalier Universitaire Vaudois
Phase 1/2 Terminated
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00124124 2015-02-13
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
Bhardwaj, Nina, M.D.
Phase 1 Completed
NCT00651703 2010-11-15
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Cytos Biotechnology AG
Phase 2 Completed